Evolocumab lowers LDL-C with no effect on glucose metabolism

LAS VEGAS – Evolocumab, an investigational antibody that inhibits PCSK9, reduces levels of low-density lipoprotein cholesterol in hypercholesterolemic patients who have dysglycemia or metabolic...